Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Could a pill replace your CPAP machine? A phase 3 trial of AD109 — a once-nightly oral combo drug — cut breathing interruptions by 44% in adults with obstructive sleep apnea who couldn't tolerate CPAP. The FDA has accepted the drug's application for review, with a decision expected by February 28, 2027. If approved, it would be the first oral medication for OSA.
Obstructive sleep apnea (OSA) affects millions, but CPAP — the current gold-standard treatment — is notoriously hard to stick with. Now, a promising oral alternative is moving through the FDA pipeline. AD109, a fixed-dose combination of aroxybutynin and atomoxetine, targets the neuromuscular dysfunction that causes the airway to collapse during sleep. In the phase 3 SynAIRgy trial (646 adults across 69 U.S. and Canadian sites), AD109 cut breathing interruptions by 44% versus 18% for placebo. The FDA has accepted Apnimed's New Drug Application, with a PDUFA target action date of February 28, 2027 — and if approved, AD109 would be the first oral pharmacologic therapy for OSA.
Pooled data from both phase 3 trials (SynAIRgy and LunAIRo, totaling 1,265 patients) reinforced these findings, showing consistent benefits across disease severity levels, BMI classes, and demographic subgroups. AD109 also meaningfully reduced snoring and improved blood oxygen levels throughout the night.
By the Numbers
Why it matters: Fewer than 40% of diagnosed OSA patients maintain long-term CPAP use. An effective, well-tolerated pill could dramatically expand treatment access — and potentially reduce the cardiovascular, metabolic, and neurocognitive risks tied to untreated OSA.
